1. 801PBone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel. (23rd October 2018) Authors: Lara, P N; Mayerson, E; Gertz, E; Tangen, C; Goldkorn, A; van Loan, M; Hussain, M; Gupta, S; Zhang, J; Twardowski, P; Quinn, D I; Vogelzang, N J; Thompson, I; Agarwal, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA8PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. (24th November 2019) Authors: Sandhu, S K; Hussain, M; Mateo, J; Fizazi, K; Saad, F; Shore, N; Chi, K; Sartor, O; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; Twardowski, P; Mehra, N; Goessl, C; Kang, J; Burgents, J; Wu, W; Kohlmann, A; Adelman, C; de Bono, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗